

30-12-2011

Submission of comments on 'Commission Guidelines on Good Distribution Practice of Medicinal Products for Human Use'

Comments from:

Name of organisation or individual

Irén dr. Kocsi

Please note that these comments and the identity of the sender will be published unless a specific justified objection is received.

When completed, this form should be sent to the European Medicines Agency electronically, in Word format (not PDF).



1. General comments

Stakeholder number	General comment (if any)	Outcome (if applicable)
(To be completed by the Agency)		(To be completed by the Agency)
	n/a	

2. Specific comments on text

Line number(s) of the relevant text (e.g. Lines 20-23)	Stakeholder number	Comment and rationale; proposed changes	Outcome
	(To be completed by the Agency)	(If changes to the wording are suggested, they should be highlighted using 'track changes')	(To be completed by the Agency)
Chapter 5; Section 5.17		Comment: To explain the term of "other products" in the glossary would be beneficial. Proposed change (if any):	
Chapter 9; Section 9.12		Comment: To explain the term of "transportation hubs" in the glossary would be beneficial. Proposed change (if any):	
n/a		Comment: n/a Proposed change (if any):	

Please add more rows if needed.